These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 11818641)

  • 41. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
    N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone.
    Antoniucci D; Migliorini A; Parodi G; Valenti R; Rodriguez A; Hempel A; Memisha G; Santoro GM
    Circulation; 2004 Apr; 109(14):1704-6. PubMed ID: 15066943
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimizing the use of abciximab and intracoronary stents in patients with acute ST elevation myocardial infarction.
    Velianou JL; Al-Suwaidi J; Mathew V
    Am J Cardiovasc Drugs; 2002; 2(5):315-22. PubMed ID: 14727961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up.
    Mukherjee D; Topol EJ; Bertrand ME; Kristensen SD; Herrmann HC; Neumann FJ; Yakubov SJ; Bassand JP; McClure RR; Stone GW; Ardissino D; Moliterno DJ;
    Eur Heart J; 2005 Dec; 26(23):2524-8. PubMed ID: 16107485
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Abciximab offers greater benefits to insulin-dependent diabetic patients undergoing coronary stent implantation.
    López-Mínguez JR; Nogales JM; González R; Palanco C; Doncel J; Vaello A; Giménez F; Morales A; Alonso R; Merchán A
    Cardiovasc Revasc Med; 2007; 8(3):175-82. PubMed ID: 17765647
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The initial experience of the use of ReoPro in high-risk coronary angioplasty in Italy: the Italian Registry on the Conditions for the Use of ReoPro during Angioplasty (R.I.CO.R.D.A.)].
    Simonetti I; Gallopin M; Klugmann S; Gensini GF
    Ital Heart J Suppl; 2000 Jan; 1(1):88-96. PubMed ID: 10832124
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?).
    Kalyanasundaram A; Blankenship JC; Berger P; Herrmann H; McClure R; Moliterno D
    Catheter Cardiovasc Interv; 2007 Apr; 69(5):623-9. PubMed ID: 17192960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation.
    Velianou JL; Mathew V; Wilson SH; Barsness GW; Grill DE; Holmes DR
    Am J Cardiol; 2000 Nov; 86(10):1063-8. PubMed ID: 11074200
    [TBL] [Abstract][Full Text] [Related]  

  • 53. One-year clinical outcome after abciximab bolus-only compared with abciximab bolus and 12-hour infusion in the Randomized EArly Discharge after Transradial Stenting of CoronarY Arteries (EASY) Study.
    Bertrand OF; Rodés-Cabau J; Larose E; Nguyen CM; Roy L; Déry JP; Courtis J; Nault I; Poirier P; Costerousse O; De Larochellière R
    Am Heart J; 2008 Jul; 156(1):135-40. PubMed ID: 18585508
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial.
    Mehilli J; Ndrepepa G; Kastrati A; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Kufner S; Dirschinger J; Berger PB; Schömig A
    Am Heart J; 2007 Jul; 154(1):158.e1-7. PubMed ID: 17584569
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial].
    Galache Osuna JG; Sánchez-Rubio J; Calvo I; Diarte JA; Lukic A; Placer LJ
    Rev Esp Cardiol; 2006 Jun; 59(6):567-74. PubMed ID: 16790200
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention.
    Stabile E; Nammas W; Salemme L; Sorropago G; Cioppa A; Tesorio T; Ambrosini V; Campopiano E; Popusoi G; Biondi Zoccai G; Rubino P
    J Am Coll Cardiol; 2008 Oct; 52(16):1293-8. PubMed ID: 18929239
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM; Mark DB; Tcheng JE; Califf RM; Bala MV; Anderson KM; Davidson-Ray L; Knight JD; Cabot CF; Topol EJ
    Circulation; 2000 Dec; 102(24):2923-9. PubMed ID: 11113041
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of multilesion coronary artery disease with simultaneous drug-eluting and bare-metal stent implantation: clinical follow up and angiographic mid-term results.
    Mirabella F; Francaviglia B; Capodanno D; Di Salvo ME; Galassi AR; Ussia GP; Capranzano P; Tamburino C
    J Invasive Cardiol; 2009 Apr; 21(4):145-50. PubMed ID: 19342750
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention.
    Huang R; Sacks J; Thai H; Goldman S; Morrison DA; Barbiere C; Ohm J
    Catheter Cardiovasc Interv; 2005 May; 65(1):25-33. PubMed ID: 15800889
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.
    Moliterno DJ; Yakubov SJ; DiBattiste PM; Herrmann HC; Stone GW; Macaya C; Neumann FJ; Ardissino D; Bassand JP; Borzi L; Yeung AC; Harris KA; Demopoulos LA; Topol EJ;
    Lancet; 2002 Aug; 360(9330):355-60. PubMed ID: 12241774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.